Clinically Relevant Characterization and Comparison of Ryaltris and Other Anti-Allergic Nasal Sprays.

corticosteroids dissolution test for inhalation products nasal cast deposition nasal drug delivery

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
26 Jul 2024
Historique:
received: 11 06 2024
revised: 23 07 2024
accepted: 24 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

The deposition, residence time, and dissolution profile of nasal suspensions containing corticosteroids play a key role in their in vivo efficacy after administration. However, the conventional methods available to characterize nasal products appear to be unsuitable to exhaustively cover these aspects. The work aims to investigate technological aspects of Ryaltris (mometasone furoate and olopatadine hydrochloride nasal spray) compared to other commercial anti-allergic nasal products, namely, Dymista (azelastine hydrochloride and fluticasone propionate), Nasonex (mometasone furoate), and Avamys (fluticasone furoate). Innovative characterization methods were combined with more traditional approaches to investigate the anti-allergic nasal sprays. These methods applied together allowed to differentiate between the different products and provided a clear picture of the nasal product behavior in terms of drug dissolution and deposition. In particular, the dissolution tests were performed exploiting the Respicell

Identifiants

pubmed: 39204334
pii: pharmaceutics16080989
doi: 10.3390/pharmaceutics16080989
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Menarini Group
ID : Private financial support

Auteurs

Virginia Patterlini (V)

Dipartimento di Scienze Degli Alimenti e del Farmaco, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

Fabiola Guareschi (F)

Dipartimento di Scienze Degli Alimenti e del Farmaco, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

Davide D'Angelo (D)

Dipartimento di Scienze Degli Alimenti e del Farmaco, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

Simone Baldini (S)

Menarini Group, Via Sette Santi 1-3, 50131 Florence, Italy.

Suada Meto (S)

Menarini Group, Via Sette Santi 1-3, 50131 Florence, Italy.

Dalia Mostafa Kamal (D)

Menarini Group, Via Sette Santi 1-3, 50131 Florence, Italy.

Paolo Fabrizzi (P)

Menarini Group, Via Sette Santi 1-3, 50131 Florence, Italy.

Francesca Buttini (F)

Dipartimento di Scienze Degli Alimenti e del Farmaco, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.
Biopharmanet-TEC, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

Ralph Mösges (R)

Institute of Medical Statistics and Computational Biology (IMSB), Medical Faculty, University at Cologne, 50923 Cologne, Germany.

Fabio Sonvico (F)

Dipartimento di Scienze Degli Alimenti e del Farmaco, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.
Biopharmanet-TEC, Università di Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

Classifications MeSH